GlaxoSmithKline’s (GSK) “Equal weight” Rating Reaffirmed at Barclays

Barclays restated their equal weight rating on shares of GlaxoSmithKline (LON:GSK) in a report released on Monday morning, ThisIsMoney.Co.Uk reports.

Several other equities research analysts also recently weighed in on GSK. Goldman Sachs Group set a $13.00 price objective on shares of Ford Motor and gave the stock a buy rating in a report on Thursday, June 13th. Credit Suisse Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Monday, May 20th. They issued a neutral rating and a $336.00 price objective for the company. Morgan Stanley assumed coverage on shares of in a report on Monday, June 17th. They issued an equal weight rating and a GBX 215 ($2.81) price target for the company. Bryan, Garnier & Co cut their price target on shares of GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating for the company in a report on Thursday, May 2nd. Finally, Jefferies Financial Group reissued a buy rating and issued a C$15.00 price target on shares of Aphria in a report on Friday, May 24th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the stock. GlaxoSmithKline currently has an average rating of Hold and an average price target of GBX 1,536.87 ($20.08).

GSK stock opened at GBX 1,661.20 ($21.71) on Monday. The firm has a market capitalization of $82.29 billion and a P/E ratio of 21.16. The business has a 50-day moving average of GBX 1,593.76. GlaxoSmithKline has a fifty-two week low of GBX 1,408.80 ($18.41) and a fifty-two week high of GBX 1,658 ($21.66). The company has a quick ratio of 0.45, a current ratio of 0.72 and a debt-to-equity ratio of 942.07.

The firm also recently declared a dividend, which was paid on Thursday, July 11th. Shareholders of record on Thursday, May 16th were issued a GBX 19 ($0.25) dividend. This represents a yield of 1.22%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s payout ratio is 0.97%.

In other news, insider Manvinder Singh Banga acquired 458 shares of GlaxoSmithKline stock in a transaction on Wednesday, May 1st. The stock was bought at an average cost of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). Insiders acquired a total of 482 shares of company stock valued at $755,935 over the last three months.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also: Beta

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.